variou
semisynthet
deriv
glycopeptid
antibiot
includ
vancomycin
eremomycin
teicoplanin
ristocetin
evalu
inhibitori
activ
felin
infecti
periton
viru
fipv
human
sarscov
strain
coronaviru
cell
cultur
comparison
activ
human
immunodefici
viru
hiv
sever
glycopeptid
deriv
modifi
hydrophob
substitu
show
select
antivir
activ
activ
compound
effect
concentr
ec
lower
micromolar
rang
gener
remov
carbohydr
part
molecul
affect
antivir
activ
compound
compound
show
inhibitori
activ
wherea
compound
prove
inhibitori
either
fipv
sarscov
close
correl
ec
valu
glycopeptid
deriv
fipv
sarscov
new
member
coronaviru
famili
identifi
caus
agent
previous
unknown
diseas
sever
acut
respiratori
syndrom
sar
ksiazek
et
al
peiri
et
al
highli
contagi
human
diseas
origin
southern
china
quickli
effici
spread
place
world
least
three
human
coronavirus
known
caus
upper
respiratori
tract
ill
account
approxim
onethird
common
cold
appear
late
fall
winter
holm
sequenc
analysi
rna
genom
sarsassoci
coronaviru
sarscov
indic
viru
genet
distinct
human
coronavirus
marra
et
al
sarscovlik
viru
isol
himalayan
palm
civet
paguma
larvata
raccoon
dog
nyctereut
pro
correspond
author
tel
fax
email
address
janbalzarini
regakuleuvenb
j
balzarini
cyonoid
sar
epidem
whose
genom
sequenc
display
ident
human
sarscov
also
song
et
al
report
genom
sequenc
sar
coronavirus
human
palm
civet
outbreak
citi
guangzhou
china
nearli
ident
recent
lau
et
al
report
isol
cov
close
relat
sarscov
human
cov
civet
wild
chines
horsesho
bat
coronavirus
seem
exist
wide
varieti
anim
includ
bovin
murin
porcin
avian
canin
felin
speci
holm
cat
coronaviru
felin
infecti
periton
viru
fipv
caus
sever
diseas
character
vascul
dissemin
pyogranulomat
lesion
variou
tissu
organ
type
ii
strain
fipv
easili
cultur
crandellrees
felin
kidney
crfk
cell
harmless
human
evalu
wide
varieti
semisyntheticmodifi
glycopeptid
antibiot
previous
found
inhibit
hiv
balzarini
et
al
printsevskaya
et
al
sidebysid
activ
sarscov
fipv
studi
aim
determin
whether
glycopeptid
antibiot
deriv
would
also
activ
sarscov
fipv
ii
whether
would
correl
structureact
relationship
coronavirus
studi
also
reveal
whether
fipv
could
use
surrog
viru
discov
activ
compound
sarscov
antivir
activ
valu
found
fipv
sarscov
studi
compar
previous
report
antihiv
data
balzarini
et
al
could
demonstr
sever
lipophyl
deriv
glycopeptid
antibiot
includ
varieti
aglycon
deriv
show
anticoronaviru
activ
lower
micromolar
rang
close
structureact
relationship
glycopeptid
deriv
virus
suggest
least
particular
class
compound
fipv
cell
cultur
model
regard
reliabl
surrog
model
screen
effici
antisarscov
inhibitor
sarscov
frankfurt
strain
kindli
provid
prof
dr
hf
rabenau
johann
wolfgang
goeth
univers
frankfurt
germani
vero
cell
propag
minim
essenti
medium
mem
gibco
life
technolog
rockvil
md
supplement
fetal
calf
serum
fc
integro
zaandam
netherland
mm
lglutamin
gibco
sodium
bicarbon
gibco
virusinfect
cell
maintain
c
co
atmospher
mem
supplement
fc
isol
fipv
strain
describ
mckeirnan
et
al
crandellrees
felin
kidney
crfk
cell
maintain
medium
gibco
supplement
foetal
calf
serum
harlan
seralab
ltd
loughborough
uk
mm
lglutamin
gibco
sodium
bicarbon
gibco
virusinfect
cell
maintain
c
medium
supplement
fc
structur
differ
class
semisynthet
glycopeptid
antibiot
deriv
present
differ
tabl
tabl
contain
manuscript
code
number
individu
compound
bold
lcta
number
laboratori
code
number
correspond
synthesi
individu
compound
chemic
synthesi
describ
earlier
work
present
report
method
chemic
modif
sugar
moieti
amid
part
resorcinol
fragment
nend
antibacteri
glycopeptid
antibiot
elabor
earlier
use
prepar
varieti
semisynthet
glycopeptid
novel
compound
obtain
method
eg
mannich
reaction
amid
nacyl
alkyl
previous
describ
synthesi
analog
glycopeptid
deriv
refer
method
prepar
compound
previous
describ
follow
pavlov
et
al
method
e
ester
obtain
analog
compound
pavlov
et
al
method
f
diamid
mixtur
mmol
mmol
appropri
amin
hydrochlorid
dissolv
ml
dmso
ad
portionwis
et
n
adjust
ph
afterward
h
mmol
pybopreag
tri
pyrrolidino
phosphoniumhexafluorophosph
reaction
mixtur
stir
room
temperatur
h
addit
ether
ml
reaction
mixtur
led
oili
residu
shaken
success
ether
ml
aceton
ml
addit
ml
aceton
precipit
collect
dri
vacuum
method
g
diamid
deriv
dmda
obtain
method
f
start
deriv
obtain
method
method
h
obtain
treatment
solut
antibiot
aglycon
dmso
equiv
dcc
dicyclohexylcarbodiimid
room
temperatur
h
addit
aceton
reaction
mixtur
led
precipit
collect
dri
vacuum
method
carboxamid
deriv
nllyzyl
deriv
teicoplanin
aglycon
octapeptid
obtain
method
c
start
nlyzylteicoplanin
aglycon
synthes
method
barna
et
al
method
k
nalkyl
deriv
teicoplanin
aglycon
obtain
method
describ
malabarba
et
al
synthesi
compound
describ
printsevskaya
et
al
compound
nagarajan
et
al
nagarajan
compound
pavlov
et
al
compound
pavlov
et
al
compound
pavlov
et
al
compound
olsufyeva
et
al
compound
miroshnikova
et
al
compound
pavlov
et
al
compound
also
printsevskaya
et
al
balzarini
et
al
compound
pavlov
et
al
compound
gerhard
et
al
compound
malabarba
et
al
compound
hermann
et
al
compound
maffiolli
et
al
compound
kannan
et
al
compound
printsevskaya
et
al
compound
berdnikova
et
al
compound
miroshnikova
et
al
compound
bognar
et
al
compound
malabarba
et
al
compound
pavlov
et
al
compound
malabarba
et
al
compound
malabarba
et
al
compound
trani
et
al
compound
malabarba
et
al
compound
cavalleri
et
al
antivir
activ
cytotox
measur
base
viabil
vero
cell
infect
mockinfect
ccid
cell
cultur
infect
dose
sarscov
keyaert
et
al
crfk
cell
infect
mockinfect
ccid
fipv
presenc
variou
concentr
fivefold
dilut
test
compound
vero
crfk
cell
seed
lwell
plate
grown
nearli
confluenc
drug
ad
cell
cultur
viru
administ
allow
compound
block
differ
step
virusinfect
process
includ
viru
adsorpt
three
day
sarscov
day
fipv
infect
number
viabl
cell
quantifi
tetrazolium
mtt
tetrazolium
bromid
sigma
chemic
co
st
loui
mo
base
colorimetr
method
previous
describ
hiv
pauwel
et
al
cytotox
concentr
determin
concentr
compound
reduc
cell
viabil
cytotox
concentr
cc
antivir
effect
concentr
determin
compound
concentr
suppress
viral
cytopath
effect
effect
concentr
ec
ec
valu
preceed
sign
mean
indic
compound
concentr
afford
antivir
activ
higher
fivefold
concentr
either
evalu
cytotox
cell
cultur
cc
valu
preceed
sign
mean
indic
compound
concentr
signific
cytotox
observ
wide
varieti
semisynthet
lipophyl
deriv
vancomycin
eremomycin
teicoplanin
demannosylndeacyl
antibiot
aglycon
deriv
deriv
thereof
glycopeptid
antibiot
modifi
partial
destroy
peptid
core
evalu
sarscov
fipv
cell
cultur
mani
compound
report
previous
endow
select
antihiv
activ
lower
micromolar
rang
balzarini
et
al
printsevskaya
et
al
iii
b
activ
test
compound
indic
tabl
compar
reason
gener
structur
investig
compound
depict
top
tabl
compound
identif
number
shown
bold
correspond
code
number
second
column
tabl
antivir
activ
repres
effect
concentr
ec
cytotox
activ
simian
kidney
vero
felin
kidney
crfk
cell
cultur
cytostat
activ
human
lymphocyt
cem
cell
cultur
repres
cytotox
concentr
cc
cytostat
concentr
ic
respect
ec
valu
fipv
sarscov
print
bold
compound
endow
select
index
ratio
cc
ec
asterix
code
number
tabl
vancomycin
eremomycin
ristomycin
teicoplanin
neither
toxic
human
cem
simian
vero
felin
crfk
cell
inhibitori
sarscov
fipv
ec
howev
introduct
hydrophob
substitu
vancomycin
eremomycin
molecul
result
new
glycopeptid
deriv
endow
anticoronaviru
activ
tabl
particular
compound
show
compar
ec
valu
rang
virus
wherea
show
pronounc
activ
fipv
ec
lesser
activ
sarscov
ec
tabl
compound
highest
activ
virus
ec
respect
howev
case
compound
sole
activ
fipv
ie
sole
activ
sarscov
ie
clear
structureact
relationship
sar
viewpoint
among
compound
bear
alkyl
substitu
nine
carbon
atom
substitut
phenyl
biphenyl
moieti
antivir
activ
antibiot
deriv
found
wherea
none
evalu
teicoplanin
deriv
show
antivir
activ
tabl
three
compound
among
deriv
found
markedli
activ
fipv
ec
lesser
activ
sarscov
ec
tabl
compound
also
note
vancomycineremomycin
deriv
contain
hydrophob
group
ring
compound
virtual
cytotox
either
vero
crfk
cell
cc
cem
cell
ic
tabl
carbohydr
moieti
remov
glycopeptid
antibiot
sever
activ
vancomycin
ere
dechlorin
deriv
result
better
antivir
activ
profil
ie
tabl
highest
number
deriv
made
within
substitut
teicoplanin
aglycon
deriv
among
sever
compound
show
pronounc
antifipv
activ
ec
valu
tabl
e
although
case
antifipv
activ
pronounc
antisarscov
activ
equal
activ
virus
interestingli
compound
sole
activ
sarscov
e
howev
clear
whether
potenti
activ
compound
fipv
mask
pronounc
cytotox
crfk
cell
vero
cell
tabl
among
teicoplanin
aglycon
deriv
amino
acid
elimin
tabl
disrupt
bond
amino
acid
tabl
tabl
sever
compound
ie
moder
activ
virus
ec
visibl
cytotox
note
howev
given
rel
high
ec
valu
exclud
viru
inhibit
rather
due
underli
toxic
compound
cell
cultur
common
structur
featur
glycopeptid
antibiot
activ
fipv
sarscov
introduct
hydrophob
substitu
molecul
requir
although
suffici
exert
antivir
activ
sever
activ
compound
ec
fipv
found
among
antibiot
bear
intact
sugar
moieti
activ
compound
fipv
sarscov
belong
aglycon
deriv
vancomycin
teicoplanin
eremomycin
increas
antivir
activ
upon
substitut
hydrophob
entiti
remov
carbohydr
part
molecul
also
note
even
pronounc
hiv
compar
data
tabl
tabl
howev
much
correl
antihiv
activ
test
compound
one
hand
antivir
activ
coronavirus
sever
potent
antihiv
compound
bare
activ
coronavirus
wherea
sever
compound
markedli
activ
coronavirus
poorli
activ
hiv
correl
coeffici
calcul
antihiv
activ
antibiot
deriv
one
hand
antifipv
antisarscov
activ
hand
rvalu
respect
found
moreov
mark
correl
found
ec
valu
compound
coronavirus
fig
inde
compound
correct
ec
valu
could
determin
taken
account
rvalu
calcul
ec
valu
glycopeptid
antibiot
fipv
sarscov
rvalu
antivir
valu
ital
denot
ec
valu
equal
lower
gml
asterix
compound
code
indic
select
cc
ec
compound
either
fipv
andor
sarscov
separ
calcul
carbohydratecontain
antibiot
tabl
aglycon
antibiot
tabl
rvalu
respect
obtain
thu
correl
somewhat
better
sole
lipophyl
aglycon
antibiot
deriv
consid
still
low
consid
felin
coronaviru
reliabl
surrog
model
replac
hazard
sarscov
cell
cultur
model
design
discoveri
novel
activ
sarscov
compound
least
within
structur
class
glycopeptid
antibiot
may
surpris
close
correl
antihiv
anticoronaviru
activ
glycopeptid
antibiot
found
previou
investig
inde
strongli
suggest
inhibit
interact
hiv
entri
target
cell
molecular
mechan
antihiv
action
observ
may
point
rather
specif
interact
compound
viral
hiv
factor
absent
coronaviru
entri
process
although
assum
glycopeptid
antibiot
akin
action
hiv
like
interfer
coronaviru
entri
process
known
human
type
ii
felin
coronavirus
recogn
differ
cellular
receptor
enter
target
cell
ie
angiotensin
convert
sarscov
felin
aminopeptidas
n
fipv
tresnan
et
al
therefor
virus
may
obvious
differ
structur
requir
optim
interact
glycopeptid
antibiot
deriv
often
rather
narrow
select
index
ratio
cc
ec
glycopeptid
antibiot
sarscov
fipv
contrast
hiv
exclud
cellular
target
rather
specif
antivir
target
compound
inde
observ
crfk
cell
use
fipv
assay
gener
sensit
toxic
effect
compound
vero
cell
use
sarscov
assay
compound
gener
also
endow
lower
ec
valu
potent
antivir
activ
fipv
sarscov
may
agreement
latter
hypothesi
elucid
molecular
basi
interact
lipophyl
glycopeptid
antibiot
cellular
viral
target
current
subject
investig
laboratori
may
lead
ration
design
potent
specif
anticoronaviru
glycopeptid
antibiot
deriv
preliminari
experi
teicoplanin
glycopeptid
antibiot
includ
timeofaddit
experi
administr
compound
delay
sever
time
period
viru
infect
refer
pyridin
noxid
compound
known
inhibit
transcript
process
balzarini
et
al
ad
control
compound
clearli
addit
glycopeptid
antibiot
virusinfect
cell
cultur
could
markedli
less
delay
fipv
infect
pyridin
noxid
compound
data
shown
ascertain
full
antivir
activ
compound
data
point
inhibit
much
earlier
event
infect
cycl
viru
target
pyridin
noxid
deriv
may
suggest
inhibit
viral
entri
process
also
shown
target
inhibit
hiv
infect
balzarini
et
al
antivir
activ
lipophyl
glycopeptid
analogu
ec
valu
coronavirus
rang
minimum
inhibitori
concentr
mic
vancomycin
teicoplanin
inhibitori
staphylococcu
aureu
sever
lipophil
glycopeptid
given
human
oritavancin
telavancin
without
acut
side
effect
therefor
possibl
therapeut
agent
base
lipophil
glycopeptid
structur
describ
studi
could
becom
use
therapeut
agent
recent
demonstr
amid
eremomycin
effect
veget
anthrax
intravascular
infect
balbc
mous
model
impli
excel
deep
tissu
penetr
pharmacokinet
paramet
obtain
singl
dose
intraven
administr
mice
show
long
halflif
min
high
tissu
level
vss
mlkg
deep
tissu
penetr
lung
spleen
comparison
vancomycin
complet
protect
mice
mous
model
inhal
anthrax
dose
low
mgkg
given
subcutan
mapl
et
al
howev
given
limit
select
index
seen
glycopeptid
antibiot
includ
studi
felt
improv
potenc
andor
select
need
made
clinic
candid
lead
compound
put
ward
structureact
relationship
studi
may
help
design
novel
compound
import
discov
new
glycopeptid
deriv
endow
potent
select
antivir
activ
lack
antibacteri
activ
fact
wherea
introduct
hydrophob
substitu
benefici
antivir
antibacteri
activ
lack
sugar
moieti
glycopeptid
molecul
often
detriment
antibacteri
activ
although
sever
hydrophob
deriv
eremomycin
teicoplanin
aglycon
known
exhibit
good
antibacteri
activ
howev
fact
antibacteri
activ
glycopeptid
deriv
evalu
studi
mainli
base
abil
inhibit
bacteri
cell
wall
biosynthesi
revers
noncoval
bind
drug
daladala
fragment
prokaryot
peptidoglycan
cell
wall
precursor
walsh
effici
dissect
fig
correl
effect
concentr
ec
glycopeptid
antibiot
deriv
fipv
crfk
cell
cultur
sarscov
vero
cell
cultur
compound
taken
account
exact
ec
valu
virus
could
determin
data
taken
tabl
must
abl
antivir
antibacteri
activ
sinc
molecular
target
peptidoglycan
synthesi
antibacteri
activ
entir
absent
virus
mammalian
cell
sever
semisynthet
lipophyl
glycon
aglycon
deriv
glycopeptid
antibiot
select
anticoronaviru
activ
cell
cultur
describ
studi
compound
inhibit
viru
infect
lower
micromolar
rang
without
measur
cytotox
although
molecular
mechan
antihiv
antifipv
action
like
viral
entri
process
close
correl
could
establish
activ
compound
coronavirus
activ
sarscov
fipv
would
appear
therefor
fipv
model
adequ
surrog
model
detect
specif
antisar
coronaviru
inhibitor
within
structur
class
glycopeptid
antibiot
